1. Pharma Division, Preclinical Research, F-Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland;
2. Department of Molecular Neuroendocrinology, Max-Planck-Institute for Experimental Medicine, 37075 Goettingen, Germany; and
3. Veterans Affairs Medical Center and Department of Psychiatry, University of California, San Diego, La Jolla, California 92093-0603